Denali Therapeutics Presents Data On Enzyme TransportVehicle Programs At 2026 WORLDSymposium
Benzinga Newsdesk 9 months ago
BiotechNewsEventsGeneral
Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority ReviewPreliminary data from Phase 1/2 study of DNL126
- Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review
- Preliminary data from Phase 1/2 study of DNL126 (ETV:SGSH) for Sanfilippo syndrome type A (MPS IIIA) to be featured in oral presentation
- Phase 1 study design of DNL952 (ETV:GAA) for Pompe disease and supporting preclinical data will appear in poster session